Health Care/Hospital
The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development
SINGAPORE, Sept. 26, 2025 /PRNewswire/ -- The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully concluded fromSeptember 24-26, 2025. The conference brought together leading biopharmaceutical companies and rese...
2025-09-27 10:45
3817
Datasea Reports Record Fiscal Year 2025 Revenue of $71.62 Million, Up 199% Year-over-Year
DTSS Achieves Fourth Quarter Net Income Breakeven Driven by Cutting-Edge Acoustics and AI Multimodal Digitalization; Ongoing Commercialization Updates in the Coming Weeks BEIJING, Sept. 26, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based high-tech ente...
2025-09-26 21:30
5514
Concord Medical Reports Financial Results for the First Half of 2025
BEIJING, Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced its unaudited consolidated financial results for t...
2025-09-26 19:30
3472
Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
BEIJING, SHANGHAI and BOSTON, Sept. 25, 2025 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK)today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million shares, repr...
2025-09-26 08:47
1935
Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001
BOSTON, Sept. 25, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation, today announced two landmark achievements for its lead program, BBT001. Last week, Ba...
2025-09-25 22:04
1964
The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer
SAN FRANCISCO, Sept. 25, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the US wholly-owned subsidiary of Beijing Biostar Biopharmaceutical Co., Ltd. ("Biostar," stock code: 2563.HK) which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of ...
2025-09-25 21:37
2263
Flat Medical Establishes Clinical Advisory Board for Pain Interventions, Names Dr. Krishnan Chakravarthy as Chairman
AUSTIN, Texas, Sept. 25, 2025 /PRNewswire/ -- Flat Medical, a leading innovator in medical device solutions, today announced the formation of itsClinical Advisory Board for Chronic Pain Interventions and the appointment of Dr. Krishnan Chakravarthy, MD, PhD, as its inaugural Chairman. This strate...
2025-09-25 21:00
1748
WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability
* TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. * The platform has achieved an average mAb titer exceeding 8.0 g/L with over 99% of clonal cell lines maintaining sta...
2025-09-25 19:42
1944
NAVER D2SF Invests in GravityLabs, a Healthcare Startup Helping Users Build Healthy Habits
- Operates "MoneyWalk", a global healthcare platform achieving more than 30 minutes of daily user engagement - Records 40% of users from overseas markets, aiming to leverage rich health data for the CRO sector - NAVER D2SF has been an early investor in healthcare startups since 2017, with expec...
2025-09-25 08:00
1925
Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials
SEOUL, South Korea and MONTREAL, Sept. 24, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, today announced a strategic partnership with CellCarta, a globally recognized provider of CRO laboratory services for p...
2025-09-24 21:00
2264
GCCL and Frontage Laboratories Announce Strategic Collaboration to Strengthen Global Clinical Trial Capabilities
YONGIN, South Korea, Sept. 24, 2025 /PRNewswire/ -- GCCL (Global Clinical Central Lab), aSouth Korea-based leading provider of clinical trial sample analysis, and Frontage Laboratories, Inc., aUSA based full-service contract research organization (CRO), announced on September 23 that they had sig...
2025-09-24 13:29
1988
Noul Secures FDA Registration for Cervical Cancer Diagnostic Cartridge
* FDA registration fulfills requirements for U.S. market entry * Initial shipments to Europe and Latin America to begin with pre-approved countries YONGIN, South Korea, Sept. 23, 2025 /PRNewswire/ -- Noul Co., Ltd. (CEO:David Lim), a medical AI company specializing in blood and cancer diagnos...
2025-09-23 21:00
1551
HKeyBio Lauched the Most Comprehesive Non-human Primate Autoimmune & Allergic Disease Model Matrix to Redefining Clinical Translation
BOSTON and SUZHOU, China, Sept. 23, 2025 /PRNewswire/ -- HKeyBio, a CRO specializing in preclinical and translational autoimmune-drug development, today announced the launch ofHKEY-NHP-MATRIX2.0, a next-generation platform designed to improve the reliability of translating novel autoimmune and al...
2025-09-23 20:35
1913
Mindray Unveils Project 2030 and Re-writes the Future of Women's Health Ultrasound at ISUOG
CANCUN, Mexico, Sept. 23, 2025 /PRNewswire/ -- On September 15th, at ISUOG 2025 World Congress inCancun, Mexico, Mindray unveiled Project 2030, an initiative to improve global access to ultrasound technology. The project was launched to an international audience of leading specialists, capping a ...
2025-09-23 13:48
1385
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year
SHANGHAI, Sept. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been selected as a constituent company of the FTSE4Good Index Series, marking the fifth consecutive year the company h...
2025-09-23 12:00
3428
Xinjiang celebrates seven decades of progress
BEIJING, Sept. 22, 2025 /PRNewswire/ -- This is a report from Beijing Review: A quiet revolution is underway in the vast cotton fields of Bortala Mongolian Autonomous Prefecture in north Xinjiang where harvesting machines, guided by digital sensors, operate with minimal human intervention. Accord...
2025-09-23 10:10
1796
GC Biopharma Submits IND Application for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea
YONGIN, South Korea, Sept. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) inSouth Korea for a Phase 1 clinical tria...
2025-09-23 09:41
1770
Global Times: China's silver economy unleashes diversified opportunities, fueling growth of multiple sectors
BEIJING, Sept. 22, 2025 /PRNewswire/ -- China is actively addressing the challenges of an aging population. As the senior population grows and their spending habits evolve, the silver economy is emerging as a driver of economic growth and industrial development. From optimizing consumption patter...
2025-09-22 21:26
1803
Global Times: China's silver economy: innovation, dignity, and shared opportunities
BEIJING, Sept. 22, 2025 /PRNewswire/ -- China's silver economy is not only transforming the lives of its senior citizens but also reshaping the global conversation about how societies should respond to demographic change. With medium-speed growth in per capita consumption, the scale ofChina's sil...
2025-09-22 21:20
1682
Galux Demonstrates De Novo Antibody Design With Structural and Functional Validation Across Eight Targets
* Study confirms the novelty and atomic-level precision of de novo antibody design, including cryo-EM validation on a designed anti-PD-L1 antibody * Findings highlight broad therapeutic applicability across oncology, immune, and metabolic diseases SEOUL, South Korea, Sept. 22, 2025 /PRNewswire...
2025-09-22 21:00
1953
Week's Top Stories
Most Reposted
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 311 media titles]
2026-02-26 09:30
Visa partners with Laufey to spread the magic of travel in Asia Pacific; to be Official Payment Partner for Laufey: A Matter of Time Tour
[Picked up by 309 media titles]
2026-03-04 12:35
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 309 media titles]
2026-02-26 19:57
SMU and Fudan Launch Region's First Tech-Focused DBA
[Picked up by 300 media titles]
2026-03-02 09:15Infobip is set to launch AgentOS to orchestrate autonomous AI-driven customer journeys at scale
[Picked up by 290 media titles]
2026-03-02 09:00
Most Read
COLUMBIA ASIA HOSPITAL BUKIT JALIL LAUNCHES NEW CATH LAB TO STRENGTHEN HEART CARE SERVICES
2026-03-02 14:24
9572
